HIV Glasgow 2022

HIV Glasgow 2022
October 23-26, 2022
Glasgow, Scotland

HIV Drug Therapy Glasgow 2022.

Explore more information for Gilead HIV / AIDS therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (8)

    Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV: 24-month (24M) analyses by age, race, sex, adherence and late presentation in a multi-country cohort study

    • Author(s): Benoit Trottier
    • biktarvy
    • HIV / AIDS

    Risk Factors Associated With ≥ ±10% Weight Change in Treatment-Naïve and Treatment-Experienced People Living With HIV Initiating or Switching to an NNRTI-or INSTI-Based Antiretroviral Therapy in Four Large Cohort Studies

    • Author(s): Olivier Robineau
    • other
    • HIV / AIDS

    ART regimen persistence among treatment-experienced patients with HIV switching to a MTR or STR since 2018

    • Author(s): Benjamin Chastek
    • other
    • HIV / AIDS

    Outcomes after switching from 144 weeks of blinded DTG/ABC/3TC or DTG+F/TAF to 96 weeks of open-label TAF

    • Author(s): Chloe Orkin
    • biktarvy
    • HIV / AIDS

    Common adverse events in clinical studies of people using lenacapavir for HIV treatment

    • Author(s): Andrea Antinori
    • lenacapavir
    • HIV / AIDS

    A pooled analysis of 8 clinical studies suggests a link between influenza-like AEs and pharmacodynamics of the TLR7 agonist VES

    • Author(s): Sharon Riddler
    • vestalimod (gs-9620)
    • HIV / AIDS

    Phenotypic Analyses of Clinical Isolates with Capsid Substitutions Observed in People with HIV (PWH) Treated with Lenacapavir

    • Author(s): Nicolas Margot
    • lenacapavir
    • HIV / AIDS

    Week 52 Subgroup efficacy analyses of long-acting subcutaneous lenacapavir in Phase 2/3 in heavily treatment-experienced people with multi-drug resistant HIV (CAPELLA study)

    • Author(s): Antonella Castagna
    • lenacapavir
    • HIV / AIDS